clinical

Sheryl brings a wealth of editorial experience to MJH Life Sciences’ Eye Care Network, having engaged with the readers and the greater ophthalmic community of 

for more than 20 years. As Group Editorial Director, Sheryl’s purview extends across the print and digital network of 

Ophthalmology Times, Ophthalmology Times Europe, Modern Retina 

 Prior to ophthalmology, Sheryl previously covered the fields of audiology and confectionery science/technology/manufacturing.

Sheryl is also passionate about the mission, vision and values of Ophthalmic World Leaders (OWL) and recently completed her term on its Board of Directors. She continues to volunteer as Editor-in-Chief of the organization’s 

Magazine. In 2013, she was honored with the group’s inaugural Rising Star Award.

In addition, she has served as a judge for 

 Health Care Heroes Awards program as well as the Jesse H. Neal National Business Journalism Awards.

Videos

Tom Ruggia, President and CEO of Samsara Vision, provides updates on the lead asset for late-state age-related macular degeneration: Smaller-incision, new generation, implantable miniature telescope (SING IMT).

Samsara Vision update: Concerto trial recruiting patients with late-stage AMD

Articles

In an attempt to halt the progression of dry AMD and geographic atrophy, the use of high-resolution optical coherence tomography becomes pivotal.

High-resolution multimodal imaging is key in dry AMD therapeutic development, future management

Lynda Charters Enoch started her early “eye life” at the Schepens Eye Research Institute, Boston, which ultimately culminated in her current position as an Editor of 

The authors noted that the proportion of patients losing fewer than 15 letters from the baseline BCVA score in the study eye was comparable between the ranibizumab and biosimilar treatment groups.

Study finds ranibizumab biosimilar equivalent in safety, efficacy for the treatment of wet AMD

The clinical trial is examining the efficacy of two doses of UBX1325 compared to every other month treatment with aflibercept through 24 weeks.

Enrollment completed for ENVISION Phase 2 clinical trial investigating UBX1325 for the treatment of AMD

Roche’s treatment of faricimab is the first and only FDA-approved medicine targeting two distinct pathways, angiopoietin (Ang)-2 and vascular endothelial growth factor (VEGF)-A, that often cause retinal diseases that may cause visual loss.

European Commission approves faricimab for treatment of wet AMD, DME

Researchers found that the rate of visual decline increased significantly in patients with age-related macular degeneration during the COVID-19 lockdown who were followed over time.

Suspension of AMD treatment during the COVID-19 pandemic resulted in increased rates of vision loss

LUNA trial will evaluate the 2x10^11 vg/eye (2E11) and a new lower 6x10^10 vg/eye (6E10) dose of Ixo-vec, with enhanced prophylactic steroid regimens in patients requiring frequent anti-VEGF injections. Interim data anticipated throughout 2023.

LUNA: First patient dosed with Ixo-vec in Phase 2 trial for treatment of wet AMD

Automated quantitative fluid analyses are enabling personalised treatments, better patient outcomes

Leveraging artificial intelligence in clinical management of nAMD

Regeneron announced that the primary endpoints were met in two pivotal trials investigating novel aflibercept 8 mg with 12- and 16-week dosing regimens in patients with diabetic macular edema and wet age-related macular degeneration.

PHOTON, PULSAR trials: Aflibercept meets primary endpoints in safety, efficacy

According to the National Institutes of Health, the therapy was derived from the patient’s blood by converting blood cells to iPS cells which were then programmed to become retinal pigment epithelial cells, which were surgically implanted as a patch of tissue.